Kinome profiling of cholangiocarcinoma organoids reveals potential druggable targets that hold promise for treatment stratification.
Cholangiocarcinoma
Drug screening
Kinome profiling
Journal
Molecular medicine (Cambridge, Mass.)
ISSN: 1528-3658
Titre abrégé: Mol Med
Pays: England
ID NLM: 9501023
Informations de publication
Date de publication:
28 06 2022
28 06 2022
Historique:
received:
22
04
2022
accepted:
13
06
2022
entrez:
28
6
2022
pubmed:
29
6
2022
medline:
1
7
2022
Statut:
epublish
Résumé
Cholangiocarcinoma is a rare but lethal cancer of the biliary tract. Its first-line treatment is currently restricted to chemotherapy, which provides limited clinical benefit. Kinase inhibitors targeting oncogenic intracellular signaling have changed the treatment paradigm of cancer over the last decades. However, they are yet to be widely applied in cholangiocarcinoma therapy. Cholangiocarcinoma has marked molecular heterogeneity, which complicates the discovery of new treatments and requires patient stratification. Therefore, we investigated whether a commercial kinome profiling platform could predict druggable targets in cholangiocarcinoma. Kinase activity in patient-derived cholangiocarcinoma organoids, non-tumorous adjacent tissue-derived and healthy donor-derived intrahepatic cholangiocyte organoids was determined using the PamChip® phosphotyrosine kinase microarray platform. Kinome profiles were compared and correlated with RNA sequencing and (multi-)kinase inhibitor screening of the cholangiocarcinoma organoids. Kinase activity profiles of individual cholangiocarcinoma organoids are different and do not cluster together. However, growth factor signaling (EGFR, PDGFRβ) and downstream effectors (MAPK pathway) are more active in cholangiocarcinoma organoids and could provide potential druggable targets. Screening of 31 kinase inhibitors revealed several promising pan-effective inhibitors and compounds that show patient-specific efficacy. Kinase inhibitor sensitivity correlated to the activity of its target kinases for several inhibitors, signifying them as potential predictors of response. Moreover, we identified correlations between drug response and kinases not directly targeted by those drugs. In conclusion, kinome profiling is a feasible method to identify druggable targets for cholangiocarcinoma. Future studies should confirm the potential of kinase activity profiles as biomarkers for patient stratification and precision medicine.
Sections du résumé
BACKGROUND
Cholangiocarcinoma is a rare but lethal cancer of the biliary tract. Its first-line treatment is currently restricted to chemotherapy, which provides limited clinical benefit. Kinase inhibitors targeting oncogenic intracellular signaling have changed the treatment paradigm of cancer over the last decades. However, they are yet to be widely applied in cholangiocarcinoma therapy. Cholangiocarcinoma has marked molecular heterogeneity, which complicates the discovery of new treatments and requires patient stratification. Therefore, we investigated whether a commercial kinome profiling platform could predict druggable targets in cholangiocarcinoma.
METHODS
Kinase activity in patient-derived cholangiocarcinoma organoids, non-tumorous adjacent tissue-derived and healthy donor-derived intrahepatic cholangiocyte organoids was determined using the PamChip® phosphotyrosine kinase microarray platform. Kinome profiles were compared and correlated with RNA sequencing and (multi-)kinase inhibitor screening of the cholangiocarcinoma organoids.
RESULTS
Kinase activity profiles of individual cholangiocarcinoma organoids are different and do not cluster together. However, growth factor signaling (EGFR, PDGFRβ) and downstream effectors (MAPK pathway) are more active in cholangiocarcinoma organoids and could provide potential druggable targets. Screening of 31 kinase inhibitors revealed several promising pan-effective inhibitors and compounds that show patient-specific efficacy. Kinase inhibitor sensitivity correlated to the activity of its target kinases for several inhibitors, signifying them as potential predictors of response. Moreover, we identified correlations between drug response and kinases not directly targeted by those drugs.
CONCLUSIONS
In conclusion, kinome profiling is a feasible method to identify druggable targets for cholangiocarcinoma. Future studies should confirm the potential of kinase activity profiles as biomarkers for patient stratification and precision medicine.
Identifiants
pubmed: 35764936
doi: 10.1186/s10020-022-00498-1
pii: 10.1186/s10020-022-00498-1
pmc: PMC9238224
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
74Informations de copyright
© 2022. The Author(s).
Références
Bioorg Chem. 2022 Mar;120:105597
pubmed: 35033817
Cell Death Dis. 2018 Jan 18;9(2):31
pubmed: 29348467
Nucleic Acids Res. 2021 Jan 8;49(D1):D884-D891
pubmed: 33137190
Chem Biol. 2008 Aug 25;15(8):808-17
pubmed: 18721752
Hepatology. 2018 Feb;67(2):762-773
pubmed: 28671339
Molecules. 2021 Dec 14;26(24):
pubmed: 34946644
Cell Stem Cell. 2021 May 6;28(5):816-832
pubmed: 33961769
Drugs. 2013 Sep;73(13):1503-15
pubmed: 23982599
Nature. 2011 May 19;473(7347):337-42
pubmed: 21593866
Nat Med. 2017 Dec;23(12):1424-1435
pubmed: 29131160
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
Cell Death Dis. 2019 Feb 11;10(2):120
pubmed: 30741922
PLoS One. 2014 Mar 20;9(3):e92146
pubmed: 24651269
Cell. 2015 Jan 15;160(1-2):299-312
pubmed: 25533785
Cancer Res. 2009 Jul 15;69(14):5987-95
pubmed: 19567681
Nat Rev Drug Discov. 2007 Sep;6(9):734-45
pubmed: 17690708
Cancer Discov. 2016 Jul;6(7):727-39
pubmed: 27231123
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Nat Rev Cancer. 2005 Mar;5(3):172-83
pubmed: 15719031
J Clin Oncol. 2012 Jan 10;30(2):134-41
pubmed: 22025146
Pharmacol Res. 2014 Jan;79:34-74
pubmed: 24269963
Proteomics. 2011 Dec;11(24):4595-609
pubmed: 22002874
Mol Cancer Ther. 2011 Dec;10(12):2215-23
pubmed: 22161785
J Cell Physiol. 2019 Mar;234(3):2984-2996
pubmed: 30058720
Cell. 2016 Apr 21;165(3):535-50
pubmed: 27104977
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Cell Rep. 2018 Jul 31;24(5):1363-1376
pubmed: 30067989
Nat Rev Cancer. 2009 Aug;9(8):537-49
pubmed: 19629069
Int J Mol Sci. 2021 Aug 12;22(16):
pubmed: 34445380
Curr Cancer Drug Targets. 2015;15(4):327-36
pubmed: 25714698
Blood. 2005 Nov 15;106(10):3423-31
pubmed: 16076871
Mol Cancer Ther. 2019 Feb;18(2):470-481
pubmed: 30381447
Nucleic Acids Res. 2021 Jan 8;49(D1):D480-D489
pubmed: 33237286
J Hepatol. 2020 Jul;73(1):170-185
pubmed: 32171892
Gastroenterology. 2020 Jul;159(1):289-305.e16
pubmed: 32171747
Nat Rev Clin Oncol. 2022 Jan;19(1):51-69
pubmed: 34561632
Cell Rep. 2019 Apr 23;27(4):1265-1276.e4
pubmed: 31018139
Drugs. 2013 Jul;73(11):1245-54
pubmed: 23846731
Nat Rev Clin Oncol. 2009 Oct;6(10):587-95
pubmed: 19787002
Expert Rev Proteomics. 2016 Jun;13(6):571-8
pubmed: 27241729